Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Adipose-derived mesenchymal stem cell-conditioned medium and proliferation of intestinal stem cells in mesenteric ischemia and reperfusion.

Yamamoto R., Suzuki S., Homma K., Maeshima K., Komura Y., Sasaki J.

Laboratory Study on Systemic / IV, published in Sci Rep (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Sci Rep (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
42401708
DOI
10.1038/s41598-026-60593-9

Abstract (original English)

Mesenteric ischemia frequently causes bowel necrosis even after recirculation, known as reperfusion injury, and no effective therapy has been validated for preserving the intestine. Adipose-derived mesenchymal stem cell-conditioned medium (MSC-CM), a tissue engineering and regenerative therapy, has been suggested as a feasible acute-phase treatment for organ damages. This study aimed to elucidate the therapeutic effects of MSC-CM on intestinal tissue injuries by ischemia and reperfusion. Mice were categorized into three groups that underwent either 60-min mesenteric artery occlusion (ischemia group), 60-min reperfusion following 60-min occlusion (reperfusion group), or ischemia-reperfusion with the same duration following intravenous administration of 200-µL MSC-CM by retroorbital injection (MSC-CM group). The distal ileum was harvested, and immunofluorescence staining with caspase-3 and LGR5, an intestinal stem cell-specific marker, was performed for evaluating the injury location and type of cells protected by MSC-CM. Moreover, LGR5, Notch1, Jagged 1, Hes1, DLL1, DLL3, and DLL4 mRNA expressions were measured using quantitative polymerase chain reaction. Ischemia extensively damaged the epithelial layer, and reperfusion-induced cellular apoptosis at the epithelial layer. MSC-CM administration was associated with preservation of cells at the crypt base, which were identified as

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research